Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

25.07 -0.14 (-0.54%)

Delayed Quote Updated: 3:18 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

April 03, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

April 01, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

March 14, 2025

From Pacira BioSciences

Via GlobeNewswire

A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts ↗

February 28, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX

March 13, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

PACIRA BIOSCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Pacira BioSciences, Inc. - PCRX

March 11, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

March 11, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

March 09, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Faruqi & Faruqi Reminds Pacira BioSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX

March 07, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2025

From Pacira BioSciences

Via GlobeNewswire

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

March 05, 2025

From SkyMedia, LLC

Via GlobeNewswire

3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX ↗

March 05, 2025

The medical sector is usually of interest during economic uncertainty, especially when it leads to heightened stock market volatility.

Via Talk Markets

Topics Stocks / Equities

PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

March 04, 2025

From Kahn Swick & Foti, LLC

Via GlobeNewswire

PCRX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX

March 03, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

March 03, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm

February 28, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

PCRX STOCKHOLDERS: Contact Robbins LLP for Information About the Pacira BioSciences, Inc. Class Action Before the Expiration of the Lead Plaintiff Deadline

February 27, 2025

From Robbins LLP

Via GlobeNewswire

Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results

February 27, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio

February 27, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March

February 26, 2025

From Pacira BioSciences

Via GlobeNewswire

For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals. ↗

February 25, 2025

PACIRA BIOSCIENCES INC has a stellar value proposition. NASDAQ:PCRX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.

Via Chartmill

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX

February 24, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX

February 21, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

February 21, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Pacira to Report 2024 Financial Results on Thursday February 27, 2025

February 20, 2025

From Pacira BioSciences

Via GlobeNewswire

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

February 19, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

February 18, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate ↗

February 14, 2025

Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery.

Via Benzinga

February 14, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.